By John Lee.
The Iraqi Ministry of Health has held high-level discussions with a delegation from French pharmaceutical company Sanofi, aimed at strengthening collaboration on biopharmaceutical development, healthcare capacity-building, and policy modernisation.
The meeting was chaired by Health Minister Dr. Saleh Mahdi Al-Hasnawi, who welcomed Sanofi's delegation led by Dr. Rami Nassar. The minister emphasised the importance of international partnerships in supporting Iraq's health sector, affirming the ministry's commitment to aligning pharmaceutical policy with global standards.
As part of the ongoing collaboration, the two sides discussed the enhancement of the "Imkan" programme, a joint initiative to improve Iraq's healthcare delivery and provide advanced training for medical personnel.
Separately, the Ministry's Directorate of Specialised Centres held a three-day scientific workshop titled "Biosimilars and Intellectual Property: Shaping Future Policy Based on Regional Experiences," under the "Imkan" programme and in partnership with Sanofi. The workshop explored regulatory frameworks for biosimilars, intellectual property rights, and evidence-based pharmaceutical policies.
Speaking on behalf of the minister, Technical Deputy Dr. Hani Al-Aqabi reiterated Iraq's intention to build strategic partnerships with global healthcare leaders. He highlighted the importance of updating Iraq's pharmaceutical regulations while protecting intellectual property and supporting local industry in line with government directives.
Dr. Ahmed Abbadi, Director of Specialised Centres, described the workshop as a vital platform for exchanging expertise. Participants included representatives from the Jordanian Food and Drug Administration, the Lebanese Ministry of Health, and various senior Iraqi health officials.
The event concluded with a recognition ceremony, awarding the "Imkan Shield" to key contributors from the ministry and Sanofi, reflecting their role in strengthening Iraq's healthcare infrastructure.
(Source: Ministry of Health)
Comments are closed.